An interventional study of renal biopsy in Lupus Nephritis (LN), sponsored by Ain Shams University. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Ain Shams University · Not applicable, Interventional, and Other
Among 20 studies in Lupus Nephritis with a site in Egypt — 8 open to participants now, 9 under way, none of them phase 3. Lupus Nephritis · Egypt.
Among the 20 studies in Lupus Nephritis with a site in Egypt, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 with no phase, and was the 17th registered.
340 studies on the registry are indexed under Lupus Nephritis; 135 are open to participants now.
Browse Lupus Nephritis studies →8 of the 20 studies in Lupus Nephritis with a site in Egypt are open now. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18+ · Healthy volunteers
Sohag University · Sites in Egypt
Ages 18–50
Sohag University · Sites in Egypt
Ages 1 mo–18 yrs
Ahmed Yehia Ismail · Sites in Egypt
Ages 18–65
Assiut University · Sites in Egypt
Ages 19+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 88 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 51 (58%) stop at 75 or younger; 29 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 1 · Phase 4 4
First in 2018; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 48 across 242 interventional studies indexed under Lupus Nephritis.
Median enrollment 63 across the 10 interventional studies, 110 across the 10 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 20 has an industry lead sponsor. The 9 most frequent:
Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ain Shams University has 4 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
2 of the studies in Lupus Nephritis with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07700940Ahmed Yehia IsmailThe Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population | 2026-12-30 |
| NCT07823556Ain Shams UniversityThe Role of Transforming Growth Factor- Beta (TGF- β) Expression in Renal Biopsy of Lupus Nephritis Patients | 2027-07-30 |
Among the 20 studies in Lupus Nephritis with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the possible role of TGF-β expression in renal biopsy and it's relation with fibrosis, activity and chronicity indices
Lupus nephritis (LN) is a common consequence of systemic lupus erythematosus and renal fibrosis is considered as a terminal pathway of the persistent immune-mediated insult .Transforming growth factor beta (TGF - β) is well recognized as a key player in LN fibrosis . A various number of cellular and molecular pathways have been incriminated as key players in the development of renal fibrosis, one of the most important main players involved in renal fibrogenesis is the transforming growth factor- β (TGF-β) signaling pathway. The investigators aim in this study to investigate the possible role of TGF-β expression in renal biopsy and it's relation with fibrosis, activity and chronicity indices
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
renal biopsy will be obtained from the participants who are indicated for it.
Procedure: renal biopsy
Kidney fibrosis will be assessed by means of needle core biopsy followed by histopathological assessment. Percutaneous kidney biopsies will be performed with ultrasonic guidance under local anaesthesia by an expert nephrologist.
Also known as: Disease activity index will be calculated by using SLEDAI, IFTA score will be calculated during histopathological assessment, and also acitivity and chronicity indices
renal biopsy
to test for the presence of Transforming Growth Factor- Beta (TGF- β) in renal biopsy of patients with lupus nephritis. All renal biopsies will be evaluated according to NIH activity and chronicity indices and fibrosis quantification according to IFTA score.
Time frame: 12 months
clinical assessment of the patient
correlation with disease activity index "SLEDAI". .
Time frame: 12 months
Started May 2026 (actual). Primary completion is estimated for Jul 2027, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.